Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
State director outlines opioid response: declines in overdose deaths, focus on naloxone, harm reduction and Medicaid waivers
Summary
Jeremy Drucker, director of the Office of Addiction and Recovery, briefed the Health Finance and Policy Committee on the state's substance use trends and multiagency response, highlighting declines in overdose deaths, the role of fentanyl, medications for opioid use disorder and plans for naloxone saturation and data integration.
Jeremy Drucker, director of the Office of Addiction and Recovery, told the Health Finance and Policy Committee March 10 that opioid‑related overdose deaths in Minnesota began to spike after fentanyl became dominant in 2019, but recent data show declines in deaths in 2023 and preliminary 2024 figures.
Drucker summarized the state’s multiagency response: prevention, harm reduction, treatment and recovery. He described medications for opioid use disorder (MOUD) — methadone, buprenorphine and naltrexone — as “particularly effective” when combined with counseling, and said harm reduction services such as naloxone…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
